Defilade Capital Management L.P. Takes Position in PTC Therapeutics, Inc. $PTCT

Defilade Capital Management L.P. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) in the first quarter, Holdings Channel reports. The institutional investor bought 376,165 shares of the biopharmaceutical company’s stock, valued at approximately $25,628,000. PTC Therapeutics accounts for approximately 3.6% of Defilade Capital Management L.P.’s portfolio, making the stock its 13th largest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PTCT. Vanguard Group Inc. boosted its stake in PTC Therapeutics by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock worth $668,691,000 after buying an additional 514,204 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after buying an additional 2,342,101 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of PTC Therapeutics by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after buying an additional 224,481 shares in the last quarter. State Street Corp raised its stake in shares of PTC Therapeutics by 34.2% in the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after buying an additional 1,071,343 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in shares of PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after acquiring an additional 891,690 shares during the period.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

Insider Activity

In other news, CAO Christine Marie Utter sold 19,686 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $75.56, for a total transaction of $1,487,474.16. Following the completion of the sale, the chief accounting officer owned 70,199 shares of the company’s stock, valued at approximately $5,304,236.44. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Neil Gregory Almstead sold 24,613 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $88.89, for a total transaction of $2,187,849.57. Following the completion of the transaction, the insider owned 60,299 shares of the company’s stock, valued at $5,359,978.11. This trade represents a 28.99% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 198,662 shares of company stock worth $16,347,994 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PTCT. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Wells Fargo & Company increased their price target on shares of PTC Therapeutics from $93.00 to $106.00 and gave the stock an “overweight” rating in a research report on Friday. Royal Bank Of Canada raised their price target on shares of PTC Therapeutics from $82.00 to $85.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Zacks Research raised PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 7th. Finally, TD Cowen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and upped their price objective for the company from $75.00 to $90.00 in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $95.75.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $68.01 on Monday. The stock has a market cap of $5.64 billion, a PE ratio of -117.26, a PEG ratio of 5.92 and a beta of 0.56. The business has a fifty day moving average of $77.57 and a two-hundred day moving average of $72.71. PTC Therapeutics, Inc. has a 52-week low of $43.17 and a 52-week high of $90.87.

PTC Therapeutics (NASDAQ:PTCT) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.68. The business had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The firm’s quarterly revenue was up 101.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.83) EPS. Analysts predict that PTC Therapeutics, Inc. will post 0.41 earnings per share for the current year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.